Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620284 | 0.81 | HTT (0.58) | HTTMAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL622749 | 0.80 | FGFR1 (0.47) | HTTMAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL28062493 | 0.78 | ALDH1A1 (0.54) | HTTMAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL12496974 | 0.78 | CYP3A4 (0.54) | HTTKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL16684318 | 0.75 | ALDH1A1 (0.43) | HTTMAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL16671515 | 0.75 | ALDH1A1 (0.43) | HTTMAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5516674 | 0.75 | LMNA (0.43) | HTTMAPTALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL622115 | 0.72 | KDM4E (0.56) | MAPTKMT2ASMN1; SMN2MEN1RAB9A | |
| SCHEMBL29550130 | 0.72 | KDM4E (0.56) | MAPTKMT2ASMN1; SMN2MEN1RAB9A | |
| SCHEMBL12817638 | 0.72 | MAPT (0.41) | HTTMAPTKMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basiliea Pharmaceutica AG | 2015-03-19 | — | — | US | disclosed |
| US-8927542-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2014-08-07 | — | — | US | disclosed |
| US-8716280-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | HTT 4619/4885MAPT 4872/4885KMT2A 3611/4885 |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | HTT 4317/4885MAPT 4699/4885KMT2A 3261/4885 |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | HTT 4317/4885MAPT 4699/4885KMT2A 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.